1. Napieralski R, et al. Establishment of a RESEARCH USE ONLY Condensed-Efficient-Fast (CEF) PITX2 workflow for analysis of PITX2 DNA methylation in small tumor tissue samples. Nature Protocol Exchange doi:10.21203/rs.2.20624/v1 (2020).

  2. Schricker, G. et al. Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer. Scientific Reports 8, 16861, doi:10.1038/s41598-018-34919-1 (2018).

  3. Schmitt, M. et al. Clinical validation of PITX2 DNA-methylation as predictor for outcome to anthracycline-based chemotherapy in high-risk breast cancer patients. Breast Care, doi:10.1159/000493016 (2018).

  4. Wilhelm, O. G. & Kiechle, M. Prognosis and Prediction in Breast Cancer: Is There a Need for Further Tests? The Journal of Applied Laboratory Medicine 3, 159-162, doi:10.1373/jalm.2018.026161 (2018).

  5. Napieralski, R. et al. therascreen PITX2 RGQ PCR assay for the assessment of PITX2 DNA-methylation status to investigate the role of the transcription factor PITX2 and the regulation of the Wnt/ß-catenin pathway in pathophysiological processes. Nature Protocol Exchange, doi: 10.1038/protex.2018.022 (2018).

  6. Absmaier, M. et al. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients. Int J Oncol 52, 755-767, doi:10.3892/ijo.2018.4241 (2018).

  7. Uhl, B. et al. PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies. J Mol Diagn 19, 107-114, doi:10.1016/j.jmoldx.2016.08.008 (2017).

  8. Aubele, M. et al. The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges. Dis Markers 2017, 4934608, doi:10.1155/2017/4934608 (2017).

  9. Wang, Q. et al. Smad4-dependent suppressor pituitary homeobox 2 promotes PPP2R2A-mediated inhibition of Akt pathway in pancreatic cancer. Oncotarget 7, 11208-11222, doi:10.18632/oncotarget.7158 (2016).

  10. Uhl, B. et al. DNA Methylation of PITX2 and PANCR Is Prognostic for Overall Survival in Patients with Resected Adenocarcinomas of the Biliary Tract. PLoS One 11, e0165769, doi:10.1371/journal.pone.0165769 (2016).

  11. Sailer, V. et al. PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma. Oncotarget 7, 75827-75838, doi:10.18632/oncotarget.12417 (2016).

  12. Luan, Z. et al. Prediction efficiency of PITX2 DNA methylation for prostate cancer survival. Genet Mol Res 15, doi:10.4238/gmr.15026750 (2016).

  13. Vasiljevic, N. et al. DNA methylation of PITX2 predicts poor survival in men with prostate cancer. Biomark Med 8, 1143-1150, doi:10.2217/bmm.14.41 (2014).

  14. Litovkin, K. et al. Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer. J Cancer Res Clin Oncol 140, 1849-1861, doi:10.1007/s00432-014-1738-8 (2014).

  15. Dietrich, D. et al. Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. J Mol Diagn 15, 270-279, doi:10.1016/j.jmoldx.2012.11.002 (2013).

  16. Dietrich, D. et al. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients. Diagn Mol Pathol 21, 93-104, doi:10.1097/PDM.0b013e318240503b (2012).

  17. Napieralski, R. et al. Emerging biomarkers in breast cancer care. Biomark Med 4, 505-522, doi:10.2217/bmm.10.73 (2010).

  18. Banez, L. L. et al. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol 184, 149-156, doi:10.1016/j.juro.2010.03.012 (2010).

  19. Weiss, G. et al. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J Urol 181, 1678-1685, doi:10.1016/j.juro.2008.11.120 (2009).

  20. Martens, J. W. M. et al. DNA methylation as a biomarker in breast cancer. Future Oncol 5, 1245-1256, doi:10.2217/fon.09.89 (2009).

  21. Hartmann, O. et al. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy. Clin Cancer Res 15, 315-323, doi:10.1158/1078-0432.CCR-08-0166 (2009).

  22. Duffy, M. J. et al. Methylated genes as new cancer biomarkers. Eur J Cancer 45, 335-346, doi:10.1016/j.ejca.2008.12.008 (2009).

  23. Nimmrich, I. et al. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer Res Treat 111, 429-437, doi:10.1007/s10549-007-9800-8 (2008).

  24. Harbeck, N. et al. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol 26, 5036-5042, doi:10.1200/JCO.2007.14.1697 (2008).

  25. Maier, S. et al. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients–Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. Eur J Cancer 43, 1679-1686, doi:10.1016/j.ejca.2007.04.025 (2007).

  26. Martens, J. W. et al. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 65, 4101-4117, doi:10.1158/0008-5472.CAN-05-0064 (2005).